Biodexa Pharmaceuticals Plc Logo

Biodexa Pharmaceuticals Plc

BDRX

()
Stock Price

4,87 USD

-69.66% ROA

-108.39% ROE

-1.08x PER

Market Cap.

42.689,68 USD

9.92% DER

0% Yield

-2282.33% NPM

Biodexa Pharmaceuticals Plc Stock Analysis

Biodexa Pharmaceuticals Plc Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Biodexa Pharmaceuticals Plc Fundamental Stock Analysis
# Analysis Rating

Biodexa Pharmaceuticals Plc Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Biodexa Pharmaceuticals Plc Technical Stock Analysis
# Analysis Recommendation

Biodexa Pharmaceuticals Plc Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Biodexa Pharmaceuticals Plc Revenue
Year Revenue Growth
2012 0
2013 147.000 100%
2014 157.000 6.37%
2015 1.375.000 88.58%
2016 1.323.000 -3.93%
2017 989.000 -33.77%
2018 1.938.000 48.97%
2019 674.000 -187.54%
2020 343.000 -96.5%
2021 578.000 40.66%
2022 699.000 17.31%
2023 166.000 -321.08%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Biodexa Pharmaceuticals Plc Research and Development Expenses
Year Research and Development Expenses Growth
2012 1.651.000
2013 2.840.000 41.87%
2014 5.439.000 47.78%
2015 8.710.000 37.55%
2016 7.730.000 -12.68%
2017 9.829.000 21.36%
2018 9.359.000 -5.02%
2019 7.843.000 -19.33%
2020 16.146.000 51.42%
2021 4.654.000 -246.93%
2022 5.111.000 8.94%
2023 3.632.000 -40.72%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Biodexa Pharmaceuticals Plc General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 2.357.000
2013 1.806.000 -30.51%
2014 4.233.000 57.34%
2015 2.081.999 -103.31%
2016 3.245.000 35.84%
2017 4.266.000 23.93%
2018 4.394.000 2.91%
2019 3.841.000 -14.4%
2020 4.958.000 22.53%
2021 2.946.000 -68.3%
2022 4.542.000 35.14%
2023 1.482.000 -206.48%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Biodexa Pharmaceuticals Plc EBITDA
Year EBITDA Growth
2012 -3.814.000
2013 -4.253.000 10.32%
2014 -7.394.000 42.48%
2015 -9.356.000 20.97%
2016 -5.302.000 -76.46%
2017 -10.609.000 50.02%
2018 -10.704.000 0.89%
2019 -10.336.000 -3.56%
2020 -9.572.000 -7.98%
2021 -6.785.000 -41.08%
2022 -8.755.000 22.5%
2023 -4.574.000 -91.41%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Biodexa Pharmaceuticals Plc Gross Profit
Year Gross Profit Growth
2012 0
2013 147.000 100%
2014 157.000 6.37%
2015 1.305.000 87.97%
2016 -6.407.000 120.37%
2017 -7.340.000 12.71%
2018 -7.421.000 1.09%
2019 -7.169.000 -3.52%
2020 -5.725.000 -25.22%
2021 -4.076.000 -40.46%
2022 -4.412.000 7.62%
2023 -4.336.000 -1.75%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Biodexa Pharmaceuticals Plc Net Profit
Year Net Profit Growth
2012 -3.994.000
2013 -4.083.999 2.2%
2014 -8.822.000 53.71%
2015 -10.099.000 12.64%
2016 -6.161.000 -63.92%
2017 -11.705.000 47.36%
2018 -10.368.000 -12.9%
2019 -9.138.000 -13.46%
2020 -22.189.000 58.82%
2021 -5.460.000 -306.39%
2022 -7.656.000 28.68%
2023 -7.022.000 -9.03%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Biodexa Pharmaceuticals Plc Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 0
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 -3.989 100%
2020 -4.144 3.74%
2021 -542 -664.39%
2022 -620 12.44%
2023 -5 -12280%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Biodexa Pharmaceuticals Plc Free Cashflow
Year Free Cashflow Growth
2012 -3.455.000
2013 -4.483.000 22.93%
2014 -6.485.000 30.87%
2015 -13.343.000 51.4%
2016 -14.433.000 7.55%
2017 -13.660.000 -5.66%
2018 -13.694.000 0.25%
2019 -6.808.000 -101.15%
2020 -9.510.000 28.41%
2021 -6.328.000 -50.28%
2022 -7.110.000 11%
2023 -1.483.500 -379.27%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Biodexa Pharmaceuticals Plc Operating Cashflow
Year Operating Cashflow Growth
2012 -3.216.000
2013 -4.436.000 27.5%
2014 -5.455.000 18.68%
2015 -12.421.000 56.08%
2016 -13.086.000 5.08%
2017 -12.953.000 -1.03%
2018 -13.450.000 3.7%
2019 -6.489.000 -107.27%
2020 -9.301.000 30.23%
2021 -6.008.000 -54.81%
2022 -7.048.000 14.76%
2023 -1.472.500 -378.64%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Biodexa Pharmaceuticals Plc Capital Expenditure
Year Capital Expenditure Growth
2012 239.000
2013 47.000 -408.51%
2014 1.030.000 95.44%
2015 922.000 -11.71%
2016 1.347.000 31.55%
2017 707.000 -90.52%
2018 244.000 -189.75%
2019 319.000 23.51%
2020 209.000 -52.63%
2021 320.000 34.69%
2022 62.000 -416.13%
2023 11.000 -463.64%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Biodexa Pharmaceuticals Plc Equity
Year Equity Growth
2012 -5.091.000
2013 760.000 769.87%
2014 41.989.000 98.19%
2015 46.887.000 10.45%
2016 45.724.000 -2.54%
2017 34.676.000 -31.86%
2018 16.924.000 -104.89%
2019 19.558.000 13.47%
2020 6.718.000 -191.13%
2021 10.452.469 35.73%
2022 3.162.000 -230.57%
2023 4.678.000 32.41%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Biodexa Pharmaceuticals Plc Assets
Year Assets Growth
2012 2.221.000
2013 5.174.000 57.07%
2014 46.663.000 88.91%
2015 64.041.000 27.14%
2016 56.689.000 -12.97%
2017 49.224.000 -15.17%
2018 20.444.000 -140.77%
2019 30.895.000 33.83%
2020 9.817.000 -214.71%
2021 12.913.000 23.98%
2022 5.525.000 -133.72%
2023 10.542.000 47.59%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Biodexa Pharmaceuticals Plc Liabilities
Year Liabilities Growth
2012 7.312.000
2013 4.414.000 -65.65%
2014 4.674.000 5.56%
2015 17.154.000 72.75%
2016 10.965.000 -56.44%
2017 14.548.000 24.63%
2018 3.520.000 -313.3%
2019 11.337.000 68.95%
2020 3.099.000 -265.83%
2021 2.460.531 -25.95%
2022 2.363.000 -4.13%
2023 5.864.000 59.7%

Biodexa Pharmaceuticals Plc Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.17
Net Income per Share
-3.98
Price to Earning Ratio
-1.08x
Price To Sales Ratio
0.18x
POCF Ratio
-1.17
PFCF Ratio
-0.01
Price to Book Ratio
1.22
EV to Sales
-23.55
EV Over EBITDA
1.25
EV to Operating CashFlow
1.12
EV to FreeCashFlow
1.11
Earnings Yield
-0.93
FreeCashFlow Yield
-115
Market Cap
0,00 Bil.
Enterprise Value
-0,01 Bil.
Graham Number
17.73
Graham NetNet
0.21

Income Statement Metrics

Net Income per Share
-3.98
Income Quality
0.92
ROE
-1.08
Return On Assets
-0.5
Return On Capital Employed
-0.9
Net Income per EBT
0.95
EBT Per Ebit
1.24
Ebit per Revenue
-19.32
Effective Tax Rate
-0.05

Margins

Sales, General, & Administrative to Revenue
8.13
Research & Developement to Revenue
12.68
Stock Based Compensation to Revenue
0.09
Gross Profit Margin
-13.55
Operating Profit Margin
-19.32
Pretax Profit Margin
-23.95
Net Profit Margin
-22.82

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-3.67
Free CashFlow per Share
-3.69
Capex to Operating CashFlow
-0
Capex to Revenue
0.1
Capex to Depreciation
0.11
Return on Invested Capital
-0.91
Return on Tangible Assets
-0.7
Days Sales Outstanding
1107.59
Days Payables Outstanding
33.94
Days of Inventory on Hand
-76.1
Receivables Turnover
0.33
Payables Turnover
10.75
Inventory Turnover
-4.8
Capex per Share
0.02

Balance Sheet

Cash per Share
4,49
Book Value per Share
3,51
Tangible Book Value per Share
1.3
Shareholders Equity per Share
3.51
Interest Debt per Share
0.35
Debt to Equity
0.1
Debt to Assets
0.04
Net Debt to EBITDA
1.26
Current Ratio
1.26
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
4973000
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.28
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
-352000
Debt to Market Cap
10.87

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Biodexa Pharmaceuticals Plc Dividends
Year Dividends Growth

Biodexa Pharmaceuticals Plc Profile

About Biodexa Pharmaceuticals Plc

Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

CEO
Mr. Stephen A. Stamp
Employee
21
Address
1 Caspian Point
Cardiff, CF10 4DQ

Biodexa Pharmaceuticals Plc Executives & BODs

Biodexa Pharmaceuticals Plc Executives & BODs
# Name Age
1 Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Company Secretary & Director
70
2 Ms. Nicola Tuckwell
Vice President & Head of Clinical Operations
70
3 Mr. Steve Ellul
Chief Business Officer
70
4 Dr. Daniel Palmer MBA, Ph.D.
Vice President of Technology
70
5 Ms. Fiona Sharp
Group Financial Controller
70

Biodexa Pharmaceuticals Plc Competitors